Navigation Links
New Pharmaceutical Company to Target Alzheimer's Disease
Date:10/21/2008

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.

Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the groundbreaking research that their team has been conducting in Florida for the past five years.

Archer Pharmaceuticals, Inc. has several compounds that are ready to enter clinical development, including ARC029 and ARC031. These compounds have been manufactured at the Sarasota-based facility to U.S. Food and Drug Administration (FDA) regulatory standards (GMP). Both are targeted at the reduction of soluble amyloid proteins in the brain -- thought by many to be the main culprits in degeneration of neurons in the brains of Alzheimer's disease sufferers. In addition, Archer Pharmaceuticals, Inc. has several other agents in the preclinical stage, including Gamma Secretase Inhibitors and BACE Inhibitors. These approaches are designed to attack the Alzheimer's disease soluble amyloid in different ways, providing complementary approaches to the lead compounds.

ARC029 was selected from approximately 2,000 agents as Archer Pharmaceuticals, Inc.'s first-line treatment for Alzheimer's because it was one of the most proficient at lowering amyloid levels in preclinical models. In these models ARC029 reduces brain amyloid levels by largely unexplored biological mechanisms.

"ARC029 acts to lower the soluble forms of amyloid before they damage the brain's neurons," said Dr. Mullan. "We believe that the soluble, rather than the deposited forms, are the real culprits in the disease, and so reducing them is our goal with this compound."

"Alzheimer's disease is a growing problem around the world, with devastating consequences for pa
'/>"/>

SOURCE Archer Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
2. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
3. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
4. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
5. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
6. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
7. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
8. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
11. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/20/2015)... Global Stem Cells Group today announced ... gathering of aesthetic medicine experts and innovators. GSCG Advisory ... the company’s brand new training course that combines facial ... , The course is designed to address the ... including facial aging caused by volume loss. , ...
(Date:4/18/2015)... PHILADELPHIA , April 18, 2015 ... (NASDAQ: CRIS ) will be presenting data ... the American Associate of Cancer Research Annual Meeting ... ).      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) ... its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3
... day that a research scientist and university professor gets to see ... few months, Richard W. Siegel will get to watch his name ... a new title that seems light years away from laboratory benches ... MAX," has been a three-year labor of love for Siegel. From ...
... IN KEY GLOBAL MARKETS, RANCHO CORDOVA, Calif., ... a leading supplier of innovative products and,services that ... it has signed,a distribution agreement with Celling Technologies ... stem cells from bone,marrow. The distribution rights are ...
... Sept. 9 For the second consecutive,year, MedNet ... study management systems, has been recognized by,Inc. magazine ... private,organizations. With consistently strong growth over the past ... in the Twin Cities,metro area, and fifth among ...
Cached Biology Technology:Professor-turned-producer learns the movie biz 2Professor-turned-producer learns the movie biz 3Professor-turned-producer learns the movie biz 4Professor-turned-producer learns the movie biz 5ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 2ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 3ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device 4MedNet Solutions Again Recognized as one of the Fastest Growing US Companies 2
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... ceremony at Oslo Concert Hall, seven pioneering researchers in ... as the first Kavli Prize laureates, receiving a gold ... Haakon Magnus. Joining His Royal Highness Crown ... of Science and Letters, the Ministry of Research of ...
... 17 September, in the context of France,s presidency of ... 2008, at the Grand Palais. The GMES (Global ... up to provide services relating to the environment, climate ... draw on data - mainly Earth observation data - ...
... test to detect whether a person might develop Alzheimer,s ... in their quest toward reversing the disease,s onset in ... Building on a study that started 20 years ago ... or in various stages of developing Alzheimer,s disease, the ...
Cached Biology News:Inaugural Kavli laureates honored in Oslo ceremony 2Major European program for the environment under the spotlight in Lille, France 2Researchers seeking to identify Alzheimer's risk focus on specific blood biomarker 2
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Plasmid expressing Zeocin resistance gene....
Biology Products: